Joshua Tolkien Kantrowitz MD
Associate Professor of Clinical Psychiatry at Columbia University
Join to View Full Profile
1051 Riverside DriveNew York State Psychiatric InstituteNew York, NY 10032
Phone+1 646-774-6738
Dr. Kantrowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Psychiatry, 2003 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2007 - 2026
CT State Medical License 2005 - 2007
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Conversion to Antipsychotic Monotherapy Start of enrollment: 2007 Dec 01
- N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia Start of enrollment: 2012 Mar 01
- NMDA Antagonists in Bipolar Depression Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.Preetika Govil, Joshua T Kantrowitz
CNS Drugs. 2025-03-01 - 4 citationsFinding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.Pejman Sehatpour, Joshua T Kantrowitz
Biological Psychiatry. 2025-01-15 - 1 citationsKnowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research.Joohyun Yoon, Megan R Mayer, Tala Berro, Stephanie Brazis, Joshua T Kantrowitz
Pharmaceutical Medicine. 2025-01-01
Journal Articles
- A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom MechanismsRagy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect
Press Mentions
Treatment of Tardive DyskinesiaAugust 13th, 2024- Karuna’s Experimental Schizophrenia Drug Succeeds in Advanced StudyAugust 8th, 2022
Some Caplyta Results in Schizophrenia Reach PrintJanuary 7th, 2020- Join now to see all
Grant Support
- Glutamatergic mechanisms of psychosis and target engagementNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2020–2027
- D-serine augmentation of neuroplasticity-based auditory learning in schizophreniaNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2019–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
